The Role of T/NK Cells in Anti-tumor Immunity
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (25 November 2023) | Viewed by 2110
Special Issue Editors
Interests: innate immunity; tumor immunology; natural killer cells; innate lymphoid cells; tumor microenvironment; cancer immunotherapy; immunocheckpoints
Special Issues, Collections and Topics in MDPI journals
Interests: NK cells; αβ T cells; γδ T cells; myeloid-derived suppressor cells; immunotherapy; tumor microenvironment
Special Issue Information
Dear Colleagues,
We are pleased to invite you to participate in this Special Issue focalized in tumor-infiltrating lymphocytes (TILs). TILs consist of all lymphocytic cell populations that have invaded the tumor tissue. TILs have been described in a number of solid tumors, but also play an important role in hematological malignancies. TILs are comprised primarily of cytotoxic (CD8+) and helper (CD4+) T-cells, and a smaller proportion of gamma/delta T and NK cells. Tumor-associated soluble factors and cells interacting with TILs could mediate immune evasion and tumor growth.
This Special Issue aims to dissect the cross-talk occurring in TME, helping to identify new potential biomarkers, therapeutic targets and possibly to develop novel protocols of anti-tumor immunotherapy.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: NK cells, alfa/beta T cells, gamma/delta T cells, CAR cells, monoclonal antibodies, inhibitory checkpoints, solid and hematological tumors, anti-tumor activity, tumor therapy, immunotherapy, immune-based therapy, and immune evasion.
We look forward to receiving your contributions.
Dr. Paola Vacca
Dr. Nicola Tumino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- innate immunity
- NK cells
- α/β T cells
- γ/δ T cells
- anti-tumor activity
- tumor therapy
- immunotherapy
- immune-based therapy
- TME
- immunoscore
